Consano Bio Raises $15M+ to Advance C-1101

Chronic sciatica can turn a nerve injury into a daily constraint on work, sleep, mobility and basic movement. Consano Bio has completed an oversubscribed private financing above $15M to fund C-1101, a potential disease-modifying biologic entering the evidence phase that matters most: controlled testing in patients.

The Burlington, Massachusetts company said the financing exceeded its $15M target and came from a syndicate of accredited private investors. Consano Bio did not disclose the exact amount, name the investors, assign a formal round label or provide a valuation. It said the transaction brings its total capital raised to more than $45M since the company was founded in 2023.

What Consano Bio Funded

The October 5 financing is intended to complete the ongoing Phase 1 study of C-1101 and support additional scientific and intellectual-property work around the program and other assets. Consano Bio expects enrollment to finish in early 2027 and clinical data to arrive in the first half of the year.

That timetable gives the financing a defined job. Early biotech capital can disappear into a list of experiments and manufacturing tasks that sound important but leave the next decision vague. Consano Bio is using this round to reach a recognizable handoff: a 24-patient controlled study that can begin separating an interesting biological thesis from a program capable of advancing through clinical development.

The company has not identified a lead investor or any participating investor by name. It has also not described the transaction as a Series A, Series B or another conventional round, so the defensible label is private financing rather than a stage inferred from its size.

The Clinical Question Behind C-1101

C-1101 is an investigational platelet- and plasma-derived multi-protein biologic for chronic painful lumbosacral radiculopathy, commonly called chronic sciatica. Consano Bio says the product contains consistent concentrations of cytokines, growth factors and matrix proteins. Delivered through an epidural injection, it is designed to place those proteins near the injured nerve, modulate inflammation and encourage localized cellular and tissue repair.

The commercial and clinical wager sits inside the phrase “disease modifying.” Existing care can provide temporary or incomplete symptom relief, while Consano Bio is trying to affect the underlying biology associated with nerve injury. That ambition raises the value of a successful result and the burden of proof required to earn one.

The C-1101-101 study is a randomized, controlled, double-blind, dose-escalation Phase 1 trial designed to enroll 24 adults across 3 sequential cohorts in Australia and the United States. Each participant receives a single epidural injection of C-1101 or saline. Safety and tolerability are the primary early obligations, with additional assessments of pain, physical function and sleep quality.

What the Regulatory Milestones Mean

The U.S. Food and Drug Administration cleared Consano Bio's investigational new drug application in July 2026, allowing the study to expand into U.S. sites. Consano Bio then announced FDA Fast Track designation for C-1101 in August.

Fast Track is intended to facilitate development and expedite review for drugs addressing serious conditions and unmet medical needs. It can create more frequent communication with FDA and enable procedural advantages such as rolling review. The designation does not establish that C-1101 works, and it does not replace the clinical evidence required for approval.

For Consano Bio, the regulatory sequence matters because the company can now build U.S. clinical evidence inside a more active dialogue with the agency. The practical value will show up in development decisions, study design and the quality of the data package, not in the designation alone.

The Evidence Boundary

Consano Bio entered the financing with a growing preclinical record. A peer-reviewed paper published in September 2026 reported that C-1101 reduced allodynia, a pain-sensitivity measure, in a mouse model of peripheral neuropathy. Cell studies also showed biological activity relevant to inflammation, repair and cell signaling.

The same paper makes the uncertainty visible. C-1101 produced a mixed inflammatory response in cultured cells, including increases in both pro-inflammatory and anti-inflammatory cytokines, and the authors said the mechanism requires further investigation. Consano Bio funded the work, company employees were among the authors, and the funder participated in study design and writing, while the paper states that the company was not directly involved in data collection, analysis or interpretation.

Those findings can support a clinical hypothesis. They cannot establish human safety, durable benefit or disease modification. The Phase 1 program is where the company begins converting the language of repair into evidence drawn from patients.

Leadership and the Next Handoff

Andrew Hall, Consano Bio's CEO and a board member, has experience across drug development, corporate development and biotechnology transactions. Jennifer Schmitke, PhD, the company's COO and Head of R&D, has led development, technical operations and portfolio work across large and emerging biopharma companies. Their immediate operating task is narrower than the platform ambition: finish enrollment, preserve study quality and reach the first clinical readout.

The financing gives Consano Bio time and resources to make that handoff. Investors have funded the path from preclinical rationale to controlled human evidence, while patients and regulators will decide how much of the underlying thesis survives contact with the clinic. By 1H 2027, Andrew Hall and Jennifer Schmitke should have the first clinical readout needed to decide how much of the repair thesis can responsibly move forward with patients.